Efficacy of PD-1/PDL-1 inhibitors for ovarian cancer: a systematic review and network meta-analysis.

IF 2.6 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2025-08-01 Epub Date: 2025-07-12 DOI:10.1080/14796694.2025.2530378

Narjisse Ahmadi, Chaimae Kadi, Maryam Benlamari, Zainab Gaouzi, El Mokhtar El Ouali, Amal Bouziane, Redouane Abouqal, Azeddine Ibrahimi

{"title":"Efficacy of PD-1/PDL-1 inhibitors for ovarian cancer: a systematic review and network meta-analysis.","authors":"Narjisse Ahmadi, Chaimae Kadi, Maryam Benlamari, Zainab Gaouzi, El Mokhtar El Ouali, Amal Bouziane, Redouane Abouqal, Azeddine Ibrahimi","doi":"10.1080/14796694.2025.2530378","DOIUrl":null,"url":null,"abstract":"Background: Randomized controlled trials (RCTs) have assessed the efficacy of anti-programmed cell death 1 (PD- 1)/programmed cell death ligand 1 (PD-L1), alone or combined with other therapies, for ovarian cancer. However, the optimal strategy remains unclear. This study evaluated their effectiveness as monotherapy and in combination.Methods: We conducted a systematic review and Frequentist network meta-analysis (NMA) by searching PubMed, ScienceDirect, Web of Science, Scopus, Cochrane Library, and Clinicaltrials.gov databases. This analysis included RCTs comparing PD-L1/PD-1 inhibitors, alone or in combination with other therapies.Results: Six studies involving 3,895 patients and eight treatment combinations were included. PD1/PDL1 inhibitors plus chemotherapy and PD1/PDL1 inhibitors plus ipilimumab showed the greatest progression-free survival (PFS) benefit (hazard ratio (HR) = 0.82, 95% confidence interval [CI]: 0.52-1.07; HR = 0.82, 95% CI:0.51-1.33) and overall survival (OS) (HR = 0.85, 95% CI:0.64-1.14; HR = 0.83, 95% CI:0.45-1.54). These combinations also improved overall response rates (ORR), especially with chemotherapy (OR = 3.06; 95% CI:1.42-6.60). Subgroup analysis suggested that PD-1/PD-L1 inhibitors plus chemotherapy provided the best PFS and OS in PD-L1-positive patients.Conclusion: Combining PD-1/PD-L1 inhibitors with chemotherapy or ipilimumab improved survival in ovarian cancer. However, PD-L1 expression may be a valuable biomarker for predicting the efficacy of PD-1/PD-L1 checkpoint inhibitors.Registration: This systematic review was preregistered in PROSPERO (CRD42022342057). Available from: https://www.crd.york.ac.uk/PROSPERO/view/CRD42022347967.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2637-2647"},"PeriodicalIF":2.6000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12506728/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2530378","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/12 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Randomized controlled trials (RCTs) have assessed the efficacy of anti-programmed cell death 1 (PD- 1)/programmed cell death ligand 1 (PD-L1), alone or combined with other therapies, for ovarian cancer. However, the optimal strategy remains unclear. This study evaluated their effectiveness as monotherapy and in combination.

Methods: We conducted a systematic review and Frequentist network meta-analysis (NMA) by searching PubMed, ScienceDirect, Web of Science, Scopus, Cochrane Library, and Clinicaltrials.gov databases. This analysis included RCTs comparing PD-L1/PD-1 inhibitors, alone or in combination with other therapies.

Results: Six studies involving 3,895 patients and eight treatment combinations were included. PD1/PDL1 inhibitors plus chemotherapy and PD1/PDL1 inhibitors plus ipilimumab showed the greatest progression-free survival (PFS) benefit (hazard ratio (HR) = 0.82, 95% confidence interval [CI]: 0.52-1.07; HR = 0.82, 95% CI:0.51-1.33) and overall survival (OS) (HR = 0.85, 95% CI:0.64-1.14; HR = 0.83, 95% CI:0.45-1.54). These combinations also improved overall response rates (ORR), especially with chemotherapy (OR = 3.06; 95% CI:1.42-6.60). Subgroup analysis suggested that PD-1/PD-L1 inhibitors plus chemotherapy provided the best PFS and OS in PD-L1-positive patients.

Conclusion: Combining PD-1/PD-L1 inhibitors with chemotherapy or ipilimumab improved survival in ovarian cancer. However, PD-L1 expression may be a valuable biomarker for predicting the efficacy of PD-1/PD-L1 checkpoint inhibitors.

Registration: This systematic review was preregistered in PROSPERO (CRD42022342057). Available from: https://www.crd.york.ac.uk/PROSPERO/view/CRD42022347967.

查看原文本刊更多论文

PD-1/PDL-1抑制剂治疗卵巢癌的疗效：系统综述和网络荟萃分析

背景：随机对照试验（RCTs）已经评估了抗程序性细胞死亡1 (PD- 1)/程序性细胞死亡配体1 （PD- l1）单独或与其他疗法联合治疗卵巢癌的疗效。然而，最佳策略仍不清楚。本研究评估了它们作为单一疗法和联合疗法的有效性。方法：通过检索PubMed、ScienceDirect、Web of Science、Scopus、Cochrane Library和Clinicaltrials.gov数据库，进行系统评价和Frequentist网络meta分析（NMA）。该分析包括比较PD-L1/PD-1抑制剂单独或与其他疗法联合的随机对照试验。结果：纳入6项研究，涉及3895例患者和8种治疗组合。PD1/PDL1抑制剂联合化疗和PD1/PDL1抑制剂联合伊匹单抗显示出最大的无进展生存（PFS）获益(风险比(HR) = 0.82, 95%可信区间[CI]: 0.52-1.07；HR = 0.82, 95% CI:0.51-1.33)和总生存期（OS） (HR = 0.85, 95% CI:0.64-1.14；Hr = 0.83, 95% ci:0.45-1.54)。这些组合也提高了总缓解率（ORR），特别是化疗(OR = 3.06；95%置信区间:1.42—-6.60)。亚组分析表明，PD-1/PD-L1抑制剂联合化疗在PD-L1阳性患者中提供了最佳的PFS和OS。结论：PD-1/PD-L1抑制剂联合化疗或伊匹单抗可提高卵巢癌患者的生存率。然而，PD-L1表达可能是预测PD-1/PD-L1检查点抑制剂疗效的有价值的生物标志物。注册：该系统评价在PROSPERO进行了预注册（CRD42022342057）。可从：https://www.crd.york.ac.uk/PROSPERO/view/CRD42022347967。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.